Ann: Xanamen Clinical Development & Investor Update, page-2

Impatient holders wont like this. I expected the SP to drop back to 0.009, however it seems to be holding up. It was pretty obvious that results weren't going to be released this quarter due to the fact only 34 out of 42 patients had been evaluated late may, and it's a 12 week study? So no surprises there. It was also apparent that any decision made before all results are in would be half cocked.

If you are someone who has accepted that this could be a 1 - 2 year hold before making significant gains, then this is good news. Xanamem seems to be active in the brain. Once we get results back from the target occupancy study, we can be sure that Xanamem does what its supposed to in regards of cortisol suppression. Within the next 12 months I would like to see a strategic partnership to run as many phase 2 trials in parrallel as possible. Our patent has an expiry after all.